These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 4217465

  • 21. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R.
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [Abstract] [Full Text] [Related]

  • 22. [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
    Liu DK.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Apr; 22(2):95-8, 126-7. PubMed ID: 2791764
    [Abstract] [Full Text] [Related]

  • 23. [Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
    Dowzenko A, Buksowicz C, Kuran W.
    Neurol Neurochir Pol; 1975 Apr; 9(4):487-93. PubMed ID: 1165836
    [Abstract] [Full Text] [Related]

  • 24. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM, Gatto E, Micheli F, Casas Parera I, Diaz S.
    Medicina (B Aires); 1991 Apr; 51(6):561-7. PubMed ID: 7476112
    [Abstract] [Full Text] [Related]

  • 25. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C, Romero S, Gomensoro JB.
    Acta Neurol Latinoam; 1974 Apr; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract] [Full Text] [Related]

  • 26. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M, Vardi J, Kesten M.
    Harefuah; 1972 Nov 01; 83(9):362-4. PubMed ID: 4669737
    [No Abstract] [Full Text] [Related]

  • 27. [Treatment of Parkinson's syndromes by a combination of levodopa with decarboxylase inhibitors].
    Hanzal F.
    Cesk Neurol Neurochir; 1975 Dec 01; 38(6):327-32. PubMed ID: 1192544
    [No Abstract] [Full Text] [Related]

  • 28. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH, Lees AJ, Stern GM.
    Eur Neurol; 1987 Dec 01; 27 Suppl 1():93-7. PubMed ID: 3322842
    [Abstract] [Full Text] [Related]

  • 29. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
    Birkmayer W, Birkmayer GD.
    J Neural Transm Suppl; 1986 Dec 01; 22():219-25. PubMed ID: 3097256
    [Abstract] [Full Text] [Related]

  • 30. [Study of the M-H response, of the silent period and of post-tetanic potentiation in subjects with Parkinson's disease during treatment with L-dopa or Madopar].
    Ferro Milone F, Lorizio A, Nordera G.
    Riv Neurol; 1975 Dec 01; 45(2):236-46. PubMed ID: 1179114
    [No Abstract] [Full Text] [Related]

  • 31. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
    Lombardo L, De la Garza R.
    Arch Invest Med (Mex); 1977 Dec 01; 8(2):123-8. PubMed ID: 907417
    [Abstract] [Full Text] [Related]

  • 32. Treating parkinsonism with L-dopa and carboxylase inhibitor.
    Shau-Fong K, Ho YM.
    Mod Med Asia; 1977 Sep 01; 13(9):23-5. PubMed ID: 600260
    [No Abstract] [Full Text] [Related]

  • 33. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO, von Kummer R, Eckert W, Weicker H.
    J Neurol; 1990 Feb 01; 237(1):24-8. PubMed ID: 2181074
    [Abstract] [Full Text] [Related]

  • 34. Levodopa treatment of Parkinson's syndrome: past and future.
    Pletscher A.
    Adv Neurol; 1990 Feb 01; 53():469-73. PubMed ID: 2239486
    [No Abstract] [Full Text] [Related]

  • 35. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
    Chouza C, Romero S, Gomensoro JB.
    Neurol Neurocir Psiquiatr; 1976 Feb 01; 17(4):255-68. PubMed ID: 828242
    [Abstract] [Full Text] [Related]

  • 36. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P, Chiurulla C, Gambi D, Mennuni G, Pinto F.
    Acta Neurol Belg; 1975 Feb 01; 75(1):5-10. PubMed ID: 1202895
    [Abstract] [Full Text] [Related]

  • 37. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM, Megna GF, Masi G, Specchio LM.
    Riv Patol Nerv Ment; 1974 Oct 01; 95(5):676-84. PubMed ID: 4470268
    [No Abstract] [Full Text] [Related]

  • 38. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS, Covicković-Sternić N.
    Neurologija; 1990 Oct 01; 39(2):99-105. PubMed ID: 2267052
    [Abstract] [Full Text] [Related]

  • 39. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F, Samson M, Pouliquen A, Hacpille L.
    Therapie; 1976 Oct 01; 31(5):615-22. PubMed ID: 1013953
    [No Abstract] [Full Text] [Related]

  • 40. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G, Casacchia M, Zamponi A, Agnoli A.
    Schweiz Rundsch Med Prax; 1976 May 04; 65(18):557-9. PubMed ID: 989900
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.